PLAT and hematocrit: For instance, tPA, the only thrombolytic agent approved by the U.S. Food and Drug Administration, has a narrow therapeutic window of 4.5 hours (h) after stroke onset [8] and increases the chances of hemorrhagic transformation (HT) [9,10].